A real‐world study of chidamide for patients with peripheral t‐cell lymphoma in china

Background: Peripheral T-cell lymphoma (PTCL) is featured with a poor survival outcome. Targeting histone deacetylases (HDACs) has become a novel treatment option for PTCL. Chidamide is the first oral selective HDAC inhibitor. Objective: This observational study aimed to investigate the efficacy and safety of Chidamide in patients with PTCL. Methods: From June 2015 to April 2022, 49 PTCL patients treated with Chidamide were included in this study. Objective responses, progression-free survival (PFS), overall survival (OS), and safety were analyzed. Results: The median age was 59 years (range, 30–85 years). Angioimmunoblastic T-cell lymphoma (AITL, 57.1%) was the main pathological subtype, followed by PTCL-not otherwise specified (PTCL-NOS, 14.3%), NK/T-cell lymphoma (NKTCL, 8.2%), anaplastic large cell lymphoma (ALCL, 6.1%) and other subtypes (14.3%). 77.6% of patients were previously untreated. 91.8% of patients had stage Ⅲ/Ⅳ disease. Thirty-three patients achieved objective responses with an overall response rate (ORR) of 67.4%, including 21 patients with complete response (CR). The 2-year PFS rate and 2-year OS rate were 51.5% and 68.5%, respectively. Among the 27 previously untreated patients who received Chidamide combined with chemotherapy, the ORR of all various PTCL subtypes, AITL and PTCL-NOS were 85.2%, 68.8% and 75.0%, respectively. The most common adverse events (AEs) were hematological toxicities. 24.5% of patients reduced the dosage or stopped using Chidamide due to AEs. No treatment-related death occurred. Conclusion: The favorable efficacy and safety profiles indicate that Chidamide would be a new therapeutic option in patients with PTCL. Encore Abstract - previously submitted to EHA 2023 Keyword: Aggressive T-cell non-Hodgkin lymphoma No conflicts of interests pertinent to the abstract.